Preparation and evaluation of β-cyclodextrin-based nanosponges loaded with Budesonide for pulmonary delivery
Creating effective drug delivery systems for pulmonary applications is fascinating challenge. Recently, we have reported on the progress Aquilon Pharma made using cyclodextrins to deliver different APIs, their lead compounds being budasonide.
In this paper Francesco Trotta‘s and Aliasgar Shahiwala‘s groups proposes an alternative solution using cyclodextrin nanosponges. In vitro and in vivo studies showed almost complete drug release and drug absorption from the lungs in the initial 2 h for pure BUD, which were sustained up to 12 h from BUD loaded into nanosponges.
